When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Prediction market on kalshi. If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.

Liquidity: $117.66. Resolves: 1/8/2027.